Transdermal hormone therapy in postmenopausal women: A review of metabolic effects and drug delivery technologies

Drug Design, Development and Therapy

Volumn , Issue 2, 2008, Pages 193-202

  Kopper, Nathan W ^a   Gudeman, Jennifer ^a   Thompson, Daniel J ^a  

^a KV Pharmaceutical Company   (United States)

Author keywords

Estradiol; Hormone therapy; Menopause; Transdermal drug delivery; Vasomotor symptoms

Indexed keywords

ACTIVATED PROTEIN C; ALPHA TOCOPHEROL; C REACTIVE PROTEIN; CIMICIFUGA RACEMOSA EXTRACT; CLONIDINE; ESTRADIOL; GABAPENTIN; GESTAGEN; LIVER PROTEIN; MEDROXYPROGESTERONE; SEX HORMONE BINDING GLOBULIN; VENLAFAXINE;

ADVERSE OUTCOME; BLOOD FLOW; CANCER RISK; CIMICIFUGA RACEMOSA; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; HORMONAL THERAPY; HUMAN; LIFESTYLE MODIFICATION; LIVER METABOLISM; MENOPAUSAL SYNDROME; METABOLISM; PATIENT COMPLIANCE; REVIEW; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

EID: 77953672043     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/dddt.s4146     Document Type: Review

References (96)

1. Abbas A, Fadel PJ, Want Z, et al. 2004. Contrasting effects of oral versus transdermal estrogen on serum amyloid A (SAA) and high-density lipoprotein-SAA in post-menopausal women. Arterioscler Thromb Vasc Biol, 24:e164-67.
2. ACOG Task Force on Hormone Therapy. 2004. Hormone therapy. Obstet Gynecol, 104(suppl):1s-131s.
3. [AACE] American Association of Clinical Endocrinologists. 2006. AACE medical guidelines for clinical practice for management of menopause. Endocrinol Pract, 12:315-337
4. Anderson GL, Limacher M, Assaf AR, et al; Women's Health Initiative Steering Committee. 2004. Effects of conjugated equine estrogen in post-menopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA, 291:1701-1712
5. Ansbacher R. 2001. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol,184:255-263 (Pubitemid 32208274)
6. Archer DF, EstroGel Study Group. 2003. Percutaneous 17-beta-estradiol gel for the treatment of vasomotor symptoms in post-menopausal women. Menopause, 10:516-521
7. Archer DF. 2003. Percutaneous 17-beta estradiol gel for the treatment of vasomotor symptoms in post-menopausal women. Menopause, 10:516-521
8. Bachmann GA. 2005. Menopausal vasomotor symptoms: a review of causes, effects, and evidence-based treatment options. J Reprod Med, 50:155-165
9. Balfour JA, Heel RC. 1990. Transdermal estradiol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs, 40:561-582 (Pubitemid 20359604)
10. Blake J. 2006. Menopause: evidence-based practice. Best Pract Res Clin Obstet Gynaecol, 20:799-839.
11. Bonduki CE, Lourenco DM, Baracat E, et al. 1998. Effect of estrogen-progestin hormone replacement therapy on plasma antithrombin III of post-menopausal women. Acta Obstet Gynecol Scand, 77:330-333 (Pubitemid 28120909)
12. Buster JE, Koltun WD, Pascual MLG, et al. 2008. Low-dose estradiol spray to treat vasomotor symptoms. Obstet Gynecol, 111:1343-1351
13. Campagnoli C, Ambroggio S, Biglia N, Sismondi P. 1999. Conjugated estrogens and breast cancer risk. Gynecol Endocrinol, 13 (Suppl 6):13-19 (Pubitemid 30068320)
14. Campagnoli C, Biglia N, Altare F, et al. 1993. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol, 7:251-258 (Pubitemid 24042454)
15. Cano A. 1994. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas, 20:91-99
16. Canonico M, PluBureau G, Lowe GDO, et al. 2008. Hormone replacement therapy and the risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ, 336:1227-1231 (Pubitemid 351809317)
17. Canonico M, Oger E, Plu-Bureau G, et al. 2007. Hormone therapy and venous thromboembolism among post-menopausal women. Impact of the route of estrogen administration and progestogens: the ESTHER Study. Circulation, 115:840-845 (Pubitemid 46294724)
18. Chetkowski RJ, Meldrum DR, Dteingold KA, et al. 1986. Biologic effects of transdermal estradiol. N Engl J Med, 314:1615-1620
19. Decensi, A, Omodei U, Chris Robertson C, et al. 2002. Effect of transdermal estradiol and oral conjugated estrogens on C-reactive protein in retinoid-placebo trial in healthy women. Circulation, 106:1224-1228 (Pubitemid 34988640)
20. de Visser MCH, Rosendaal FR, Bertina RM. 1999. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood, 93:1271-1276 (Pubitemid 29076142)
21. Divigel® PI. 2007. Divigel® prescribing information. Minneapolis, Minnesota, USA: Upsher Smith. June 2007.
22. Doherty JA, Cushing-Haugen KL, Saltzman BS, et al. 2007. Long-term use of post-menopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol, 197:139e1-e7.
23. Ehara S, Ueda M, Naruko T, et al. 2001. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation, 103:1955-2160 (Pubitemid 32322222)
24. Elestrin® PI. 2007. Elestrin® prescribing information. Fairfield, New Jersey, USA: Kenwood Therapeutics. January 2007.
25. Erianne JA, Winter L, Jr. 1997. Comparison of local tolerability and adhesion of a new matrix system (Menorest®) for estradiol delivery with an established transdermal membrane system (Estraderm TTS®). Maturitas, 26:95-101.
26. Estraderm® PI. 2005. Estraderm® prescribing information. Hanover, NJ, USA: Novartis. January 2005.
27. Evamist™ PI. 2008. Evamist™ prescribing information. St. Louis, MO, USA: Ther-Rx Corporation. January 2008.
28. Fletcher B, Berra K, Ades P, et al. 2005. AHA Scientific Statement: Managing Abnormal Blood Lipids. A collaborative approach. Circulation, 112:3184-3209
29. Fugate SE, Church CO. 2004. Nonestrogen treatment modalities for vasomotor symptoms associated with menopause. Ann Pharmacother, 38:1482-1499 (Pubitemid 39100205)
30. Gleason CE, Carlsson CM, Johnson S, et al. 2005. Clinical pharmacology and differential cognitive efficacy of estrogen preparation. Ann NY Acad Sci, 1052:93-115. (Pubitemid 41338961)
31. Gomes MPV, Deitcher SR. 2004. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med, 164:1965-1976 (Pubitemid 39390552)
32. Grady D, Gebretsadik T, Kerlikowske K, et al. 1995. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol, 85:304-313
33. Grady D, Herrington D, Bittner V, et al. 2002. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA, 288:49-57. (Pubitemid 34705518)
34. Grodstein F, Stampfer MJ, Manson JE, et al. 1996. Post-menopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med, 335:453-461 (Pubitemid 26269944)
35. Hanggi W, Lippuner K, Riesen W, et al. 1997. Long term influence of different post-menopausal hormone replacement therapy on lipoprotein: A randomized study. Br J Obstet Gynaecol, 104:708-717 (Pubitemid 27278355)
36. Harman SM, Brinton EA, Cedars M, et al. 2005. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric, 8:3-12. (Pubitemid 40675116)
37. Henderson BE, Paganini-Hill A, Ross RK. 1988. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstest Gynecol, 159:312-317
38. Hersh AL, Stefanick ML, Stafford RS. 2004. National use of post-menopausal hormone therapy. Annual trends and response to recent evidence. JAMA, 291:47-53.
39. Hing E, Brett KM. 2003. Changes in US prescribing patterns of menopausal hormone therapy, 2001-2003. Obstet Gynecol, 108:33-40. (Pubitemid 44336842)
40. Hivonen E, Lamberg-Allardt C, Lankinen KS, Geurts P, Wilen-Rosenqvist G. 1997. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy. Br J Obstet Gynaecol, 104(Suppl 16):19-25. (Pubitemid 27501720)
41. Hope S, Rees MCP. 1995. Why do British women start and stop hormone therapy? J Br Menopause Soc, 1:26-27
42. Hylley S, Grady D, Bush T, et al. 1998. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. JAMA, 280:605-613 (Pubitemid 28502636)
43. Humphrey LL, Chan BD, Sox HC. 2002. Post-menopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med, 137:273-284
44. Kayser J, Ettinger, B, Pressman A. 2001. Postmenspausal hormone support: discontinuation of raloxifene versus estrogen. Menopause, 8:328-332 (Pubitemid 32826164)
45. Kisilevsky R, Subrahmanyan L. 1992. Serum amyloid A changes high density lipoprotein's cellular affinity: a clue to serum amyloid A's principal function. Lab Invest, 66:778-785
46. Lacut K, Oger E, Le Gal G, et al. 2003. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost, 90:124-131 (Pubitemid 36873868)
47. Liang JS, Schreiber BM, Salmona M, et al. 1996. Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells. J Lipid Res, 37:2109-2116 (Pubitemid 26357322)
48. Lobo RA. 2004. The rationale for low-dose hormonal therapy. Endocrine, 24:217-221
49. Mattsson LA, Bohnet HG, Gredmark T, et al. 1999. Continuous, combined hormone replacement: a randomized comparison of transdermal and oral preparations. Obstet Gynecol, 94:61-65 (Pubitemid 29284427)
50. McNamara JR, Jenner JL, Li A, et al. 1992. change in LDL particle size is associated with changes in plasma triglyceride concentration. Arterioscler Thromb, 12:1284-1290
51. Menon DV, Vongpatanasin W. 2006. Effects of transdermal estrogen replacement therapy on cardiovascular risk factors. Treat Endocrinol, 5:37-51. (Pubitemid 43096063)
52. Minkin MJ. 2002. Considerations in the choice of oral vs transdermal hormone therapy: A review. J Reprod Med, 49:311-320
53. Musel AL, Warshaw EM. 2006. Cutaneous reactions to transdermal therapeutic systems. Dermatitis 17:109-122
54. Nachtigall LE. 1995. Emerging delivery systems for estrogen replacement: Aspects of transdermal and oral delivery. Am J Obstet Gynecol, 173:993-997
55. Nahas EAP, Nahas-Neto J, Orsatti FL, et al. 2007. Efficacy and safety of a soy isoflavone extract in post-menopausal women: A randomized, double-blind, and placebo-controlled study. Maturitas, 58:249-258 (Pubitemid 350103531)
56. Nelson HD, Humphrey LL, LeBlanc E, et al. 2005. Hormone therapy for the prevention of chronic conditions in post-menopausal women: recommendations from the US Preventive Services Task Force. Ann Intern Med, 142:855-860
57. Newton KM, Reed SD, LaCroix AZ, et al. 2006. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo. Ann Intern Med, 145:869-879
58. Oger E, Alhenc-Gelas M, Lacut K, et al. 2003. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among post-menopausal women. A randomized trial. Arterioscler Thromb Vasc Biol, 23:1671-1676 (Pubitemid 37108215)
59. Post MS, Christella M, Thomassen LGD, et al. 2003. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: A randomized, placebo-controlled study in post-menopausal women. Arterioscler Thromb Vasc Biol, 23:1116-1121 (Pubitemid 36713570)
60. Pradhan AD; Manson JE; RossouwJE, et al. 2002. Inflammatory biomarkers, hormone replacement therapy, and incident of coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA, 288:980-987
61. Rapkin AJ. 2007. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol, 196:97-106.
62. Reginster JY, Donazzolo Y, Brion N, Lins R. 2000. Estradiol pharmacokinetics after transdermal application of patches to post-menopausal women: matrix versus reservoir patches. Climacteric, 3:168-175
63. Ridker PM, Cushman M, Stampfer MJ, et al. 2000. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 342:836-843 (Pubitemid 30165206)
64. Rodeghiero F, Tosetto A. 1999. Activated protein C resistance and factor V Leiden are independent risk factors for venous thromboembolism. Ann Intern Med, 130:643-650 (Pubitemid 29196198)
65. Rossouw JE, Anderson GL, Prentice RL, et al. 2002. Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288:321-333
66. Rossouw JE, Prentice RL, Manson JE, et al. 2007. Post-menopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 297:1465-1477 (Pubitemid 46556472)
67. Sacks F, Walsh B. 1994. Sex hormones and lipoprotein metabolism. Curr Opin Lipidol, 5:236-240
68. Samsioe G. 2004. Transdermal hormone therapy: gels and patches. Climacteric, 7:347-356 (Pubitemid 40021797)
69. Sattar N, Perera M, Small M, et al. 1999. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. Lancet, 354:487-488 (Pubitemid 29368936)
70. Scarabin PY, Oger E, Plu-Bureau G, et al. 2003. Differential associatin of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet, 362:428-432 (Pubitemid 36999704)
71. Schmidt JW, Wollner D, Curcio J, et al. 2006. Hormone replacement therapy in menopausal women: Past problems and future possibilities. Gynecological Endocrinology, 22:564-577 (Pubitemid 44885096)
72. Scott RT, Jr, Ross B, Anderson C, et al. 1991. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol, 77:758-764
73. Shulman LP, Yankov V, Uhl K. 2003. Safety and efficacy of a continuous once-a-week 17β-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in post-menopausal women: The results of two multicenter, double-blind, randomized, controlled trials. Menopause, 9:195-207.
74. Simon JA, Bouchard C, Waldebaum A, et al. 2007. Low dose of transdermal estradiol gel for treatment of symptomatic post-menopausal women: a randomized controlled trial. Obstet Gynecol, 109:588-596 (Pubitemid 46339398)
75. Simon JA, Ravnikar V. 2007. Transdermal estrogen therapy: evidence and update. The Female Patient, November Supplement.
76. Simon JA. 2004. New options in transdermal administration. OBG Management, November Supplement, 16-19
77. Simon JA, Estrasorb Study Group. 2006. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause, 13:222-231 (Pubitemid 43755877)
78. Skouby SO, Gram J, Anderson LF, et al. 2002. Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. Am J Obstet Gynecol, 186:969-977
79. Smith SC, Jr, Anderson JL, Cannon RO 3rd, et al. 2004. CDC/AHA Workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice: report from the clinical practice discussion group. Circulation, 110:e550-3.
80. Soules MR, Sherman S, Parrott E, et al. 2001. Executive summary: stages of reproductive aging workshop (STRAW). Menopause, 8:402-407 (Pubitemid 33031310)
81. Speroff L, the United States VR Investigator Group. 2003. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol, 102:823-834
82. Stampfer MJ, Colditz GA, Willett WC, et al. 1991. Post-menopausal estrogen therapy and cardiovascular disease: ten year follow-up from the nurses' health study. N Engl J Med, 325:756-762
83. Stampfer MJ, Willett WC, Colditz GA, et al. 1985. A prospective study of post-menopausal estrogen therapy and coronary heart disease. N Engl J Med, 313:1044-1049 (Pubitemid 16243331)
84. Stephenson J. 2003. FDA orders estrogen safety warnings: agency offers guidance for HRT use. JAMA, 289:537-538 (Pubitemid 37428620)
85. Straczek C, Oger E, Yon de Jonage-canonico MB, et al. 2005. Prothrombotic mutations, hormone therapy and venous thromboembolism among post-menopausal women. Circulation, 112:3495-3500
86. Strandberg TE, Olavi Ylikorkala O, Tikkanen MJ. 2003. Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women. Am J Cardiol, 92:212-214 (Pubitemid 36835975)
87. Stumpf PG. 1990. Pharmacokinetics of estrogen. Obstet Gyneco, 75(Suppl):9s-17s.
88. Sturdee D, Archer D, Rakov V, et al. 2008. Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in post-menopausal women. Climacteric, 11:63-73.
89. Sturdee DW, Archer DF, Rakov V, et al. 2008. Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in post-menopausal women. Climacteric, 11:68-73.
90. The North American Menopause Society. 2007. Estrogen and progestogen use in peri- and post-menopausal women: March 2007 position statement of the North American Menopause Society. Menopause, 14:168-182
91. [NAMS] The North American Menopause Society. 2003. Role of progestogen in hormone therapy for post-menopausal women: position statement of The North American Menopause Society. Menopause,10:113-132
92. Van Baal W M, Kenemans P, van der Mooren MJ, et al. 1999. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost, 81:925-928 (Pubitemid 29312709)
93. Vehkavaara S, Hakala-Ala-Pietilä T, Virkamäki A, et al. 2000. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in post-menopausal women. Circulation, 102:2687-2693
94. Vongpatanasin W, Tuncel M, Wang Z, et al. 2003. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol, 41:1358-1363 (Pubitemid 36438997)
95. Wakatsuki A, Okatani Y, Ikenoue N, et al. 2002. Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in post-menopausal women. Circulation, 106:1771-1776
96. Weissberger AJ, HO KKY, Lazarus L. 1991. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in post-menopausal women. J Clin Endocrinol Metab, 72:374-381 (Pubitemid 21921702)